Pacira Pharmaceuticals Inc (PCRX)

Current ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Total current assets	US$ in thousands	509,994	447,255	429,324	376,114	498,334	533,411	526,210	667,018	866,048	822,352	792,579	720,247	651,623	658,520	455,823	431,594	408,557	378,847	394,609	508,673
Total current liabilities	US$ in thousands	97,383	93,661	108,912	98,698	147,774	131,526	133,179	305,073	521,118	225,788	228,693	232,084	253,328	86,272	70,583	80,313	107,673	95,838	83,004	58,991
Current ratio		5.24	4.78	3.94	3.81	3.37	4.06	3.95	2.19	1.66	3.64	3.47	3.10	2.57	7.63	6.46	5.37	3.79	3.95	4.75	8.62

December 31, 2023 calculation

Current ratio = Total current assets ÷ Total current liabilities
= $509,994K ÷ $97,383K
= 5.24

Based on the data provided for Pacira BioSciences Inc's current ratio over the past eight quarters, we observe fluctuations in the ratio. The current ratio, which measures the company's ability to meet its short-term obligations with its current assets, has shown a general upward trend since Q1 2022.

The current ratio increased from 2.19 in Q1 2022 to 5.24 in Q4 2023, indicating a significant improvement in the company's short-term liquidity position. This suggests that Pacira BioSciences Inc has ample current assets to cover its current liabilities, providing a strong financial position.

However, it is worth noting that there have been fluctuations in the current ratio over the quarters, such as the decrease from 4.06 in Q3 2022 to 3.37 in Q4 2022. These fluctuations could be due to changes in the composition of current assets and liabilities or variations in the company's operating cycle.

Overall, the upward trend in Pacira BioSciences Inc's current ratio over the quarters indicates an improvement in its short-term liquidity position and ability to meet its financial obligations. Investors and analysts may view this positively as it suggests a stronger financial foundation for the company.